Treatment of onychomycosis in Mexico

References

• Arenas R, Bonifaz A, Padilla MC et al. Onychomycosis: a Mexican survey. Eur. J. Dermatol. 20, 611–614 (2010).
   PubMedGoogle Scholar
• Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J. Clin. Pharm. Ther. 35(5), 497–519 (2010).
   PubMed Web of Science ®Google Scholar
• Shirwaikar AA, Thomas T, Shirwaikar A, Lobo R, Prabhu KS. Treatment of onychomycosis: an update. Indian J. Pharm. Sci. 70(6), 710–714 (2008).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Schouten JR, Lynch LE. Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective. Skin Therapy Lett. 10(7), 1–3 (2005).
   PubMedGoogle Scholar
• Aristimuño M, Arenas R, Rubalcaba-Priego J et al. [Onicomicosis en pacientes diabéticos tipo 2 ambulatorios. Datos clínico-epidemiológicos y tratamiento con bifonazol-urea]. Dermatol. Rev. Mex. 44, 60–68 (2000).
   Google Scholar
• Bonifaz A, Ibarra G. Onychomycosis in children: treatment with bifonazole-urea. Pediatr. Dermatol. 17(4), 310–314 (2000).
   PubMed Web of Science ®Google Scholar
• Romero-Cerecero O, Román-Ramos R, Zamilpa A, Jiménez-Ferrer JE, Rojas-Bribiesca G, Tortoriello J. Clinical trial to compare the effectiveness of two concentrations of the Ageratina pichinchensis extract in the topical treatment of onychomycosis. J. Ethnopharmacol. 126(1), 74–78 (2009).
   PubMedGoogle Scholar
• Singal A, Khanna D. Onychomycosis: Diagnosis and management. Indian J. Dermatol. Venereol. Leprol. 77(6), 659–672 (2011).
   PubMed Web of Science ®Google Scholar
• Trivedi NA, Shah PC. A meta-analysis comparing efficacy of continuous terbinafine with intermittent itraconazole for toenail onychomycosis. Indian J. Dermatol. 55(2), 198–199 (2010).
   PubMedGoogle Scholar
• Arenas R, Domínguez-Cherit J, Fernández LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int. J. Dermatol. 34(2), 138–143 (1995).
   PubMedGoogle Scholar
• Bonifaz A, Carrasco-Gerard E, Saúl A. Itraconazole in onychomycosis: intermittent dose schedule. Int. J. Dermatol. 36(1), 70–72 (1997).
   PubMedGoogle Scholar
• Dominguez-Cherit J, Teixeira F, Arenas R. Combined surgical and systemic treatment of onychomycosis. Br. J. Dermatol. 140(4), 778–780 (1999).
   PubMedGoogle Scholar
• Arenas R, Fernández G, Domínguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int. J. Dermatol. 30(8), 586–589 (1991).
   PubMedGoogle Scholar
• Gilaberte Y, Aspiroz C, Martes MP, Alcalde V, Espinel-Ingroff A, Rezusta A. Treatment of refractory fingernail onychomycosis caused by nondermatophyte molds with methylaminolevulinate photodynamic therapy. J. Am. Acad. Dermatol. 65(3), 669–671 (2011).
   PubMed Web of Science ®Google Scholar
• Chiacchio ND. Comment on the article ‘Use of high frequency waves for the treatment of onychomycosis – preliminary report of three cases’. An. Bras. Dermatol. 86(4), 831 (2011).
   PubMedGoogle Scholar
• Gupta AK, Uro M, Cooper EA. Onychomycosis therapy: past, present, future. J. Drugs Dermatol. 9(9), 1109–1113 (2010).
   PubMed Web of Science ®Google Scholar
• Vásquez-del Mercado E, Arenas R. Onychomycosis among children. A retrospective study of 233 Mexican cases. Gac. Med. Mex. 144(1), 7–10 (2008).
   PubMedGoogle Scholar
• Bonifaz A, Cruz-Aguilar P, Ponce RM. Onychomycosis by molds. Report of 78 cases. Eur. J. Dermatol. 17(1), 70–72 (2007).
   PubMed Web of Science ®Google Scholar
• Arenas-Guzman R, Tosti A, Hay R, Haneke E; National Institute for Clinical Excellence. Pharmacoeconomics – an aid to better decision-making. J. Eur. Acad. Dermatol. Venereol. 19(Suppl. 1), 34–39 (2005).
   PubMed Web of Science ®Google Scholar
• Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br. J. Dermatol. 166(2), 389–398 (2012).
   PubMed Web of Science ®Google Scholar
• Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin. Dermatol. 28(2), 151–159 (2010).
   PubMed Web of Science ®Google Scholar
• Lurati M, Baudraz-Rosselet F, Vernez M et al. Efficacious treatment of non-dermatophyte mould onychomycosis with topical amphotericin B. Dermatology (Basel) 223(4), 289–292 (2011).
   PubMed Web of Science ®Google Scholar
• Barot BS, Parejiya PB, Patel HK, Gohel MC, Shelat PK. Microemulsion-based gel of terbinafine for the treatment of onychomycosis: optimization of formulation using D-optimal design. AAPS PharmSciTech 13(1), 184–192 (2012).
   PubMed Web of Science ®Google Scholar
• Elewski BE, Ghannoum MA, Mayser P et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J. Eur. Acad. Dermatol. Venereol. doi:10.1111/j.1468-3083.2011.04373.x (2011) (Epub ahead of print).
   Google Scholar